View Author
cancer patient breast tumor breast cancer study level tamoxifen protein expression methylation breast cancer patients status bcar 1 -10 cells prognostic marker disease analysis survival therapy sample dc-script treatment serum progesterone adjuvant receptor c-h 2ax bcar 1 levels result value -10 assay factor biomarker tissue table haptoglobin cluster research model activity netherland cyp 2c prostate cancer methylated response prognostic value promoter phenotype group tumour metabolism outcome prostate genotype association pregnenolone 53 bp 1 hazard detection methylated genes menopausal status recurrence department breast tumors speci tamoxifen therapy allele esr 1 esr 2 cohort hypermethylation prognosis leydig seldi-tof number metabolite figure
10 Most Recent Publications
|
Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer
(Article)
Gast, M.C.W. Zapatka, M. Tinteren, H. van Bontenbal, M. Span, P.N. Tjan-Heijnen, V.C.G. Knol, J.C. Jimenez, C.R. Schellens, J.H.M. Beijnen, J.H. |
2011-12-01
|
|
Constitutive expression of γ-H2AX has prognostic relevance in triple negative breast cancer
(Article)
Nagelkerke, A. Kuijk, S.J.A. van Sweep, F.C.G.J. Nagtegaal, I.D. Hoogerbrugge, N. Martens, J.W.M. Timmermans, M.A. Laarhoven, H.W.M. van Bussink, J. Span, P.N. |
2011-10-01
|
|
The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients
(Article)
Schaik, R.H.N. van Kok, M. Span, P.N. Laarhoven, H.W.M. van Sleijfer, S. Foekens, J.A. Linn, S.C. Berns, E.M.J. Sweep, F.C.J. Vliet, M. van Fessem, M.A. van Meijer van Gelder, M.E. Seynaeve, C.M. Lindemans, J. Wesseling, J. Veer, L.J. van 't |
2011-08-01
|
|
Overexpression of the natural antisense hypoxia-inducible factor-1α transcript is associated with malignant pheochromocytoma/paraganglioma
(Article)
Span, P.N. Rao, J.U. Timmers, H.J.L.M. Oude Ophuis, S.B.J. Lenders, J.W.M. Sweep, F.C.G.J. Wesseling, P. Kuster, B. Nederveen, F.H. van Krijger, R.R. de Hermus, A.R.M.M. |
2011-06-01
|
|
Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: An independent retrospective validation study
(Article)
Sieuwerts, A.M. Ansems, M. Look, M.P. Span, P.N. Weerd, V. de Galen, A. van Foekens, J.A. Adema, G.J. Martens, J.W.M. |
2010-12-01
|
|
Methylated genes as new cancer biomarkers
(Article)
Duffy, M.J. Napieralski, R. Martens, J.W.M. Span, P.N. Spyratos, F. Sweep, F.C. Brünner, N. Foekens, J.A. Schmitt, M. |
2009-02-01
|
|
Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients
(Article)
Gast, M.C.W. Tinteren, H. van Twisk, J.W. Schellens, J.H. Beijnen, J.H. Bontenbal, M. Hoesel, R.Q.G.C.M. van Nooij, M.A. Rodenhuis, S. Span, P.N. Tjan-Heijnen, V.C.G. Vries, E. de Harris, N. |
2008-12-24
|
|
The prognostic value of BCAR1 in patients with primary breast cancer.
(Article)
Dorssers, L.C.J. Grebenchtchikov, N. Tienoven, D.T. van Geurts-Moespot, A. Span, P.N. Foekens, J.A. Sweep, F.C. Brinkman, A. Look, M.P. Broekhoven, S.P. van Jong, D. de Peters, H.A. Portengen, H. Meijer van Gelder, M.E. Klijn, J.G.M. |
2004-09-15
|
|
Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer.
(Article)
Dorssers, L.C.J. Grebenchtchikov, N. Brinkman, A. Look, M.P. Klijn, J.G.M. Geurts-Moespot, A. Span, P.N. Foekens, J.A. Sweep, C.G. |
2004-08-01
|
|
Implications of progesterone metabolism in MA-10 cells for accurate measurement of the rate of steroidogenesis
(Article)
Rommerts, F.F.G. King, S.R. Span, P.N. |
2001-01-01
|
